Spl-memantine-chemical-structure (Spl Memantine Chemical Structure)
Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 47335-322
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 47335-322). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Spl-memantine-figure1 (Spl Memantine Figure1)
This is a graph showing the time course of change in ADCS-ADL score for patients completing 28 weeks of treatment with either Placebo or Memantine Hydrochloride. The graph indicates clinical improvement with Memantine Hydrochloride compared to Placebo.*
Spl-memantine-figure2 (Spl Memantine Figure2)
The provided text is a figure caption showing a graph of the percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. The plot compares the effectiveness of two drugs, Placebo and Memantine Hydrochloride, in treating Alzheimer's disease. The graph shows the percentage of patients at different levels of improvement in their ADCS-ADL scores from baseline. There is no additional information available in the provided text.*
Spl-memantine-figure3 (Spl Memantine Figure3)
The text describes a graph labeled as "Figure 3" that shows the time course of change from baseline in SIB (Severe Impairment Battery) score for patients who completed 28 weeks of treatment. The graph includes two lines representing the mean change from baseline for a placebo group and a group treated with memantine hydrochloride. There are also labels for clinical improvement and clinical decline.*
Spl-memantine-figure4 (Spl Memantine Figure4)
The text describes a figure labeled as "Figure 4", which shows the cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB scores. The figure also includes two drugs, "Placebo" and "Memantine Hydrochloride".*
Spl-memantine-figure5 (Spl Memantine Figure5)
The text describes a figure showing the time course of change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment with either placebo/donepezil or memantine hydrochloride/donepezil. It indicates that there was clinical improvement in the ADCS-ADL score over 24 weeks of treatment with memantine hydrochloride/donepezil. However, there is no information available about the baseline or the conditions being treated.*
Spl-memantine-figure6 (Spl Memantine Figure6)
The text appears to be the results of a clinical trial for treatments of Alzheimer's disease. Two treatments are mentioned, Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The graph shows the percentage of patients completing 24 weeks of treatment and their corresponding changes from baseline in ADCS-ADL scores. Unfortunately, without more context, it's difficult to draw any meaningful conclusion about the effectiveness of the treatments.*
Spl-memantine-figure7 (Spl Memantine Figure7)
This is a figure showing the time course of change from baseline in SIB score for patients who completed 24 weeks of treatment with either placebo/donepezil or memantine hydrochloride/donepezil. The figure is divided into weeks of treatment on the x-axis and mean change from baseline on the y-axis. No further information is available in the text.*
Spl-memantine-figure8 (Spl Memantine Figure8)
This is a graph showing the Cumulative Percentage of Patients completing a 24-week double-blind treatment with specified changes from baseline in SIBscores. There are two different treatments shown; Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis shows the change in SIBscores from baseline, ranging from -30 to +20, and the y-axis shows the cumulative percentage of patients who achieved that change.*
Spl-memantine-label-10mg (Spl Memantine Label 10mg)
Spl-memantine-label-5mg (Spl Memantine Label 5mg)
This is a prescription medicine with the name Memantine Hydrochloride Tablets, identified by NOC 47335-321.86, which comes in the form of a bottle containing 60 tablets distributed by SUN. Other than that, the text is not available for evaluation.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
